Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors
The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.
The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.